Loading clinical trials...
Loading clinical trials...
Phase II Trial of Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma
The primary objective of this trial is to estimate efficacy of the novel regimen. The primary endpoint is the 1-year PFS rate after treatment with one dose of pembrolizumab followed by four to six cycles of chemo-immunotherapy with P-BrECADD, and PET-guided radiotherapy as per standard of care
Age
18 - 60 years
Sex
ALL
Healthy Volunteers
No
1st Department of Medicine, Cologne University Hospital
Cologne, Germany
Start Date
August 1, 2025
Primary Completion Date
January 1, 2027
Completion Date
January 1, 2029
Last Updated
April 6, 2025
40
ESTIMATED participants
Pembrolizumab
DRUG
Lead Sponsor
University of Cologne
NCT05529069
NCT06189391
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05006716